Fremanezumab reduced migraine attacks and depression symptoms in migraine patients with major depressive disorder.

Following the sell-off, Lilly trades at a forward price-to-earnings (P/E) of 37 times 2025 analyst estimates, with a price-to ...

Eli Lilly officials and Gov. Mike Braun break ground on the LEAP District's Lilly Medicine Foundry, a $4.5 billion project ...

Zepbound is the preferred weight loss medicine vs. Wegovy and has consistently beaten the latter in U.S. weekly prescriptions ...

Eli Lilly Chairman and CEO Dave Ricks joins 'Mornings with Maria' to discuss his meeting with President Donald Trump, the ...

LLY is bullish in weekly sequence from all time low. It favors rally in (V) after double correction ended at $677.09 low in ...

CompanyOverview|NYSE:LLY] The world’s largest pharmaceutical stock, Eli Lilly and Company (NYSE: LLY), recently had its worst ...

Under terms of the deal, Alchemab will lead early Phase I trials for ATLX-1282 in amyotrophic lateral sclerosis, while Lilly ...

Lilly plans to break ground Tuesday afternoon on its $4.5 billion Lilly Medicine Foundry in Lebanon. Lilly Chair and CEO Dave ...

Financial terms of the new agreement include an upfront payment to secure rights to Alchemab's lead ALS candidate, ATLX-1282, ...

Following President Trump's executive order, the Indian pharmaceutical industry anticipates a surge in unannounced ...